$599

Kailera Valued at $1.9B as it Eyes IPO; Diamyd Discontinues DIAGNODE-3 Trial

Two cardiometabolic-related news items have been observed: Kailera Therapeutics released its IPO pricing (view SEC filing) and Diamyd Medical discontinued its Ph3 DIAGNODE-3 trial evaluating retogatein (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register
Already a member? Log in here